Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: C: moxifloxacin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

NCT02027454
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744, GSK1265744 matching placebo, Moxifloxacin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

NCT01913002
View directory record Official record
Conditions
Healthy
Interventions
LX4211 800 mg, LX4211 2000 mg, moxifloxacin 400 mg, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction - Oral Contraceptive

NCT00399685
View directory record Official record
Conditions
HIV Infections
Interventions
Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
San Diego, California • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Oral Contraceptive Pill (OCP)

NCT01063023
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Ortho Tri-Cyclen®, BMS-650032
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

NCT03155893
View directory record Official record
Conditions
Healthy
Interventions
ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV), ODV Placebo (Matching 100 mg ODV), SMV Placebo (Matching 150 mg SMV), AL-335 Placebo (matching 1200 mg AL-335), Moxifloxacin Placebo (matching 400 mg moxifloxacin), ODV 25 mg, ODV 200 mg, ODV 125 mg, ODV 100 mg, SMV 150 mg, AL-335 1200 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

NCT03613649
View directory record Official record
Conditions
Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions
AZD0914, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

NCT02165332
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Electrophysiological Effects of Potential QT Prolonging Drugs

NCT05716854
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Clarithromycin, Pimozide, Placebo (Part 1), Moxifloxacin, Cobicistat, Moxifloxacin and Cobicistat, Placebo (Part 2)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

NCT02084953
View directory record Official record
Conditions
Hepatitis C
Interventions
BMS-791325, Moxifloxacin, Placebo matching BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

NCT05995444
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Epetraborole and matching placebo, Epetraborole, Placebo, Moxifloxacin
Drug
Lead sponsor
AN2 Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

NCT01191723
View directory record Official record
Conditions
Healthy
Interventions
MAP0004, Inhaler Placebo, Moxifloxacin, Placebo Capsule
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

NCT01613040
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Moxifloxacin, RO4917838, RO4917838 placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)

NCT00890565
View directory record Official record
Conditions
Healthy
Interventions
granisetron
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

NCT07074327
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults

NCT00850746
View directory record Official record
Conditions
Functional Dyspepsia
Interventions
YM443, Placebo, Moxifloxacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

NCT02222324
View directory record Official record
Conditions
Healthy Subjects
Interventions
Placebo, E2609, Moxifloxacin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

NCT07272629
View directory record Official record
Conditions
Cardiac Repolarization, Healthy Volunteers
Interventions
Balinatunfib, Moxifloxacin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

NCT03258515
View directory record Official record
Conditions
Solid Tumors
Interventions
AZD6094 200 mg, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

NCT01353729
View directory record Official record
Conditions
Influenza, Human
Interventions
600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 29, 2026, 4:45 PM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

NCT05241535
View directory record Official record
Conditions
Healthy Subjects
Interventions
MT-7117, moxifloxacin, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 29, 2026, 4:45 PM EDT
Suspended Phase 3 Interventional

Intracameral Antibiotic Safety Study

NCT02590523
View directory record Official record
Conditions
Intracameral Antibiotics, Cataract Surgery, Phacoemulsification, Endophthalmitis, Vancomycin, Moxifloxacin
Interventions
Vancomycin, Moxifloxacin, Placebo
Drug
Lead sponsor
Panhandle Eye Group, LLP
Other
Eligibility
30 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine Thorough QT/QTc

NCT00543062
View directory record Official record
Conditions
Cardiotoxicity
Interventions
Inhaled placebo, Oral placebo, Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Oral moxifloxacin
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Sep 29, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

NCT02152332
View directory record Official record
Conditions
Healthy
Interventions
JNJ-54861911-Therapeutic Dose, JNJ-54861911 - Supratherapeutic Dose, JNJ-54861911-Matched Placebo, Moxifloxacin, Moxifloxacin Matched Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 29, 2026, 4:45 PM EDT